Drug:
Reaction: THERAPY INTERRUPTED
20250101 - 20251231
No. 801 - 900
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 801 | 25035931 |
44 | 2 | |
Influenza, Therapy interrupted, |
||||
ETANERCEPT, |
||||
| 802 | 25035936 |
56 | 2 | |
Pneumonia, Therapy interrupted, |
||||
ETANERCEPT, |
||||
| 803 | 25035946 |
59 | 2 | |
Plasma cell myeloma, Therapy interrupted, |
||||
IXEKIZUMAB, |
||||
| 804 | 25036248 |
2 | ||
Influenza, Therapy interrupted, |
||||
TERIPARATIDE, |
||||
| 805 | 25036375 |
55 | 2 | |
Illness, Therapy interrupted, |
||||
CAPSAICIN, CAPSAICIN, CALCITRIOL, CALCITRIOL CAPSULES 0.25 MCG, CALCITRIOL CAPSULES 0.5 MCG, CETIRIZINE HCL, CETIRIZINE, |
||||
| 806 | 25036442 |
ET |
23 | 2 |
Drug ineffective, Therapy interrupted, |
||||
FLUOXETINE HYDROCHLORIDE, FLUOXETINE, FLUOXETINE HYDROCHLORIDE, FLUOXETINE, |
||||
| 807 | 25036483 |
US |
||
Increased intraperitoneal volume, Wrong technique in product usage process, Product preparation error, Device leakage, Therapy interrupted, Abdominal distension, |
||||
ICODEXTRIN, SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE, |
||||
| 808 | 25036920 |
US |
||
Dementia, Therapy interrupted, |
||||
VUTRISIRAN, |
||||
| 809 | 25036949 |
US |
2 | |
Hospitalisation, Oxygen saturation abnormal, Heart rate abnormal, Dyspepsia, Abdominal discomfort, Therapy interrupted, |
||||
AMIKACIN, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, IBUPROFEN, IBUPROFEN AND DIPHENHYDRAMINE CITRATE, |
||||
| 810 | 25037211 |
US |
1 | |
Hospitalisation, Therapy interrupted, |
||||
PIMAVANSERIN TARTRATE, ALPRAZOLAM, AMANTADINE, AMOXICILLIN, CARBIDOPA LEVODOPA, ENTACAPONE, MEMANTINE, MEMANTINE HYDROCHLORIDE, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, SERTRALINE, |
||||
| 811 | 25037254 |
US |
1 | |
Hallucination, Constipation, Therapy interrupted, |
||||
PIMAVANSERIN TARTRATE, PIMAVANSERIN TARTRATE, AMANTADINE, DONEPEZIL HYDROCHLORIDE, DROXIDOPA, GABAPENTIN, OXYBUTYNIN, TESTOSTERONE, TESTOSTERONE,, |
||||
| 812 | 25037400 |
39 | 1 | |
Thrombocytopenia, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 813 | 25037411 |
US |
64 | 2 |
Therapy interrupted, Device difficult to use, Accidental exposure to product, Device use error, Arthritis, Product communication issue, |
||||
ETANERCEPT, ETANERCEPT, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, |
||||
| 814 | 25037471 |
US |
64 | 2 |
Product distribution issue, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 815 | 25037513 |
62 | 2 | |
Respiratory tract infection, Therapy interrupted, |
||||
UPADACITINIB, |
||||
| 816 | 25037958 |
US |
||
Therapy interrupted, Product availability issue, |
||||
ESTRADIOL, |
||||
| 817 | 25037962 |
US |
2 | |
Fungal skin infection, Eye pain, Foreign body sensation in eyes, Wrong technique in product usage process, Therapy interrupted, |
||||
CENEGERMIN-BKBJ, GABAPENTIN, OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN, |
||||
| 818 | 25038217 |
US |
||
Drug ineffective, Therapy interrupted, |
||||
| 819 | 25038427 |
US |
2 | |
Therapy interrupted, Psoriasis, |
||||
APREMILAST, SERTRALINE HYDROCHLORIDE, |
||||
| 820 | 25038515 |
AU |
2 | |
Psoriatic arthropathy, Body tinea, Therapy interrupted, Drug ineffective, Product prescribing issue, |
||||
BIMEKIZUMAB, |
||||
| 821 | 25038547 |
US |
||
Brain fog, Mood swings, Hot flush, Night sweats, Therapy interrupted, |
||||
RELUGOLIX, ESTRADIOL HEMIHYDRATE, AND NORETHINDRONE ACETATE, |
||||
| 822 | 25038694 |
US |
86 | 1 |
Insurance issue, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 823 | 25040603 |
49 | 2 | |
Illness, Therapy interrupted, |
||||
ETANERCEPT, |
||||
| 824 | 25040604 |
68 | 2 | |
Infection, Therapy interrupted, |
||||
ETANERCEPT, |
||||
| 825 | 25040610 |
76 | 1 | |
Illness, Therapy interrupted, |
||||
ADALIMUMAB, |
||||
| 826 | 25040644 |
45 | 1 | |
Influenza, Therapy interrupted, |
||||
ADALIMUMAB, |
||||
| 827 | 25040645 |
55 | 2 | |
Herpes zoster, Therapy interrupted, |
||||
UPADACITINIB, |
||||
| 828 | 25040663 |
26 | 2 | |
Infection, Therapy interrupted, |
||||
ADALIMUMAB, |
||||
| 829 | 25040665 |
2 | ||
Hospitalisation, Therapy interrupted, |
||||
TERIFLUNOMIDE, TERIFLUNOMIDE, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, |
||||
| 830 | 25040670 |
1 | ||
Cellulitis, Infection, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 831 | 25040690 |
36 | 2 | |
Colitis, Therapy interrupted, |
||||
RISANKIZUMAB-RZAA, |
||||
| 832 | 25040699 |
54 | 2 | |
COVID-19, Therapy interrupted, |
||||
IXEKIZUMAB, |
||||
| 833 | 25040713 |
56 | 2 | |
Infection, Therapy interrupted, |
||||
USTEKINUMAB, |
||||
| 834 | 25040741 |
68 | 2 | |
Therapy interrupted, Hospitalisation, |
||||
APREMILAST, |
||||
| 835 | 25040959 |
72 | 2 | |
Fall, Hip fracture, Lower limb fracture, Therapy interrupted, |
||||
OCTREOTIDE, OCTREOTIDE, PIOGLITAZONE, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, ERGOCALCIFEROL, EMPAGLIFLOZIN, METFORMIN HYDROCHLORIDE, DULAGLUTIDE, |
||||
| 836 | 25029097 |
US |
68 | 2 |
Blood test abnormal, Off label use, Therapy interrupted, |
||||
DASATINIB, |
||||
| 837 | 25029284 |
US |
59 | 1 |
Product distribution issue, Inability to afford medication, Therapy interrupted, |
||||
| 838 | 25029332 |
US |
57 | 1 |
Cough, Product prescribing issue, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 839 | 25029427 |
US |
2 | |
Metastatic neoplasm, Surgery, Cardiac disorder, Lung disorder, Therapy interrupted, |
||||
EVOLOCUMAB, |
||||
| 840 | 25029787 |
US |
54 | 1 |
Insurance issue, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 841 | 25029847 |
US |
15 | 2 |
Malaise, Therapy interrupted, |
||||
ISOTRETINOIN, |
||||
| 842 | 25029878 |
CO |
75 | 1 |
Blood pressure decreased, Dizziness, Gastrointestinal haemorrhage, Melaena, Haemoglobin decreased, Diaphragmatic hernia, Dyskinesia, Transfusion, Therapy interrupted, |
||||
ROTIGOTINE, ROTIGOTINE, ROTIGOTINE, ROTIGOTINE, ROTIGOTINE, CARBIDOPA, LEVODOPA, AND ENTACAPONE, |
||||
| 843 | 25029946 |
US |
85 | 2 |
Product distribution issue, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 844 | 25030220 |
US |
2 | |
Urinary tract infection, Therapy interrupted, |
||||
PIMAVANSERIN TARTRATE, CARBIDOPA AND LEVODOPA, |
||||
| 845 | 25030221 |
US |
82 | 1 |
Living in residential institution, Product use issue, Therapy interrupted, |
||||
PIMAVANSERIN TARTRATE, PIMAVANSERIN TARTRATE, PIMAVANSERIN TARTRATE, |
||||
| 846 | 25030430 |
US |
2 | |
Disturbance in attention, Patient dissatisfaction with treatment, Therapy interrupted, Product use in unapproved indication, |
||||
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE, |
||||
| 847 | 25030493 |
US |
70 | 1 |
Product distribution issue, Therapy interrupted, |
||||
| 848 | 25030770 |
US |
77 | 2 |
Therapy interrupted, |
||||
ABATACEPT, |
||||
| 849 | 25030909 |
IE |
2 | |
Hospitalisation, Dysphagia, Illness, Therapy interrupted, Off label use, |
||||
CLOZAPINE, CLOZAPINE, |
||||
| 850 | 25030942 |
US |
41 | 2 |
Drug hypersensitivity, Tongue dry, Herpes zoster, Pruritus, Erythema, Tongue erythema, Tongue eruption, Therapy interrupted, |
||||
| 851 | 25030950 |
US |
56 | 2 |
Insurance issue, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 852 | 25031486 |
US |
77 | 2 |
Tremor, Product use issue, Therapy interrupted, |
||||
PIMAVANSERIN TARTRATE, PIMAVANSERIN TARTRATE, PIMAVANSERIN TARTRATE, |
||||
| 853 | 25031749 |
2 | ||
Tremor, Laboratory test abnormal, Hair growth abnormal, Therapy interrupted, |
||||
CYCLOSPORINE, |
||||
| 854 | 25031889 |
US |
||
Therapy interrupted, |
||||
RELUGOLIX, |
||||
| 855 | 25031925 |
US |
2 | |
Sleep disorder, Therapy interrupted, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 856 | 25032053 |
US |
1 | |
Tremor, Therapy interrupted, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 857 | 25032618 |
US |
66 | 2 |
Dry eye, Eye pruritus, Ocular hyperaemia, Therapy interrupted, Inability to afford medication, Product dose omission in error, Product use issue, |
||||
LIFITEGRAST, |
||||
| 858 | 25032620 |
GB |
54 | 1 |
Rheumatoid arthritis, General physical health deterioration, Illness, Fatigue, Mental disorder, Drug ineffective, Therapy interrupted, |
||||
CERTOLIZUMAB PEGOL, METHOTREXATE, METHOTREXATE SODIUM, |
||||
| 859 | 25033064 |
GB |
2 | |
Fall, Product availability issue, Therapy interrupted, |
||||
CLOZAPINE, |
||||
| 860 | 25033173 |
US |
70 | 1 |
Product dispensing issue, Therapy interrupted, Illness, Pneumonia, |
||||
LENALIDOMIDE, |
||||
| 861 | 25033334 |
US |
||
Hospitalisation, Therapy interrupted, |
||||
TENAPANOR HYDROCHLORIDE, |
||||
| 862 | 25033824 |
US |
73 | 1 |
Insurance issue, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 863 | 25033963 |
US |
50 | 2 |
Therapy interrupted, Device difficult to use, |
||||
ETANERCEPT, |
||||
| 864 | 25035754 |
54 | 1 | |
Therapy interrupted, |
||||
TRALOKINUMAB-LDRM, |
||||
| 865 | 25026003 |
US |
67 | 1 |
Illness, Infection, Diarrhoea, Vomiting, Productive cough, Dizziness, Dyspnoea, Pyrexia, Therapy interrupted, Device power source issue, Device power source issue, |
||||
TREPROSTINIL, TREPROSTINIL, FUROSEMIDE, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, VITAMIN C, ADALIMUMAB, OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN, FOLIC ACID, ERGOCALCIFEROL, FLUTICASONE PROPIONATE, METHOTREXATE, METHOTREXATE SODIUM, OXYGEN, 0XYGEN, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE, FERROUS SULFATE, |
||||
| 866 | 25026124 |
US |
1 | |
Therapy interrupted, |
||||
EVOLOCUMAB, |
||||
| 867 | 25026137 |
US |
1 | |
Psoriasis, Therapy interrupted, |
||||
APREMILAST, ESCITALOPRAM, |
||||
| 868 | 25026141 |
CA |
36 | 1 |
Syncope, Oropharyngeal pain, Syncope, Fatigue, Oropharyngeal pain, Skin lesion, Psoriasis, Therapy interrupted, Dyspnoea, Arthralgia, Diarrhoea, Depressed mood, Gastrointestinal disorder, Diarrhoea, Rash, Dyspnoea, Depressed mood, Fatigue, Headache, Panic attack, Rash, Arthralgia, Product distribution issue, Disease recurrence, |
||||
ESCITALOPRAM, ESCITALOPRAM OXALATE, ESCITSLOPRAM, BRODALUMAB, BRODALUMAB, BRODALUMAB, BRODALUMAB, BRODALUMAB, |
||||
| 869 | 25021143 |
US |
||
Asthenia, Vomiting, Diarrhoea, Adverse drug reaction, Therapy interrupted, |
||||
DAPAGLIFLOZIN, |
||||
| 870 | 25021327 |
US |
2 | |
Hepatitis, Hepatic cirrhosis, Depression, Procedural pain, Therapy interrupted, Insurance issue, Inability to afford medication, |
||||
OBETICHOLIC ACID, URSODIOL, URSOSIOL, |
||||
| 871 | 25021338 |
BR |
||
Symptom recurrence, Localised infection, Off label use, Drug ineffective, Therapy interrupted, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, METHOTREXATE, METHOTREXATE SODIUM, |
||||
| 872 | 25021380 |
US |
||
Hospitalisation, Therapy interrupted, |
||||
RELUGOLIX, |
||||
| 873 | 25021529 |
US |
2 | |
Therapy interrupted, |
||||
ISOTRETINOIN, |
||||
| 874 | 25021693 |
US |
||
Glucose tolerance impaired, Prostatic specific antigen increased, Hot flush, Therapy interrupted, |
||||
RELUGOLIX, |
||||
| 875 | 25021884 |
US |
85 | 1 |
Diarrhoea, Vitamin B12 decreased, Influenza, Macular degeneration, Therapy interrupted, Product supply issue, Product availability issue, |
||||
LENALIDOMIDE, |
||||
| 876 | 25021918 |
US |
2 | |
Bronchiectasis, Painful respiration, COVID-19, Dry throat, Dysphagia, Dysgeusia, Aphonia, Aphonia, Throat irritation, Dysphonia, Adverse drug reaction, Oropharyngeal pain, Cough, Oropharyngeal discomfort, Aphonia, Unevaluable event, Tinnitus, Product dose omission issue, Therapy interrupted, Device use issue, Drug dose omission by device, Device breakage, |
||||
AMIKACIN, AMIKACIN, AMIKACIN, AMIKACIN, |
||||
| 877 | 25021983 |
US |
18 | 1 |
Therapy interrupted, |
||||
ISOTRETINOIN, |
||||
| 878 | 25022009 |
US |
2 | |
Disturbance in attention, Drug effective for unapproved indication, Patient dissatisfaction with treatment, Therapy interrupted, Product use in unapproved indication, |
||||
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE, |
||||
| 879 | 25022325 |
US |
82 | 2 |
Diarrhoea, Dizziness, Product distribution issue, Therapy interrupted, Off label use, |
||||
LENALIDOMIDE, |
||||
| 880 | 25022330 |
JP |
82 | 2 |
Rehabilitation therapy, Pyrexia, Cough, Productive cough, Therapy interrupted, Intentional dose omission, |
||||
AMIKACIN, AMIKACIN, |
||||
| 881 | 25022565 |
US |
71 | 2 |
Terminal state, Treatment noncompliance, Therapy interrupted, |
||||
CLOZAPINE, |
||||
| 882 | 25022651 |
GB |
1 | |
Schizophrenia, Malaise, Differential white blood cell count abnormal, Therapy interrupted, |
||||
CLOZAPINE, CLOZAPINE, |
||||
| 883 | 25022941 |
CO |
29 | 2 |
Liposuction, Lipectomy, Off label use, Insurance issue, Therapy interrupted, |
||||
CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, |
||||
| 884 | 25023139 |
GB |
2 | |
Sedation, Confusional state, Mental impairment, Somnolence, Therapy interrupted, Off label use, |
||||
ARIPIPRAZOLE ORALLY DISINTEGRATING, ARIPIPRAZOLE, ARIPIPRAZOLE ORAL, CLOZAPINE, CLOZAPINE, |
||||
| 885 | 25023356 |
GB |
59 | 1 |
Schizophrenia, Thrombocytopenia, Treatment noncompliance, Therapy interrupted, |
||||
CLOZAPINE, CLOZAPINE, |
||||
| 886 | 25023369 |
2 | ||
Surgery, Therapy interrupted, |
||||
BELIMUMAB, SACUBITRIL AND VALSARTAN, |
||||
| 887 | 25023486 |
US |
2 | |
Therapy interrupted, |
||||
AVACOPAN, |
||||
| 888 | 25023687 |
US |
44 | 1 |
Product distribution issue, Therapy interrupted, |
||||
THALIDOMIDE, |
||||
| 889 | 25023908 |
63 | 1 | |
Pancreatitis acute, Cholelithiasis, Biliary obstruction, Therapy interrupted, |
||||
SEMAGLUTIDE, |
||||
| 890 | 25024036 |
US |
60 | 2 |
Insurance issue, Therapy interrupted, Off label use, |
||||
LENALIDOMIDE, |
||||
| 891 | 25024054 |
2 | ||
Fall, Skull fracture, Therapy interrupted, |
||||
MACITENTAN, RIOCIGUAT, |
||||
| 892 | 25024067 |
61 | 1 | |
Pneumonia, Sepsis, Lactic acidosis, Therapy interrupted, Acute respiratory failure, Emphysema, Cardiomyopathy, Cardiac failure acute, Chronic obstructive pulmonary disease, Pulmonary hypertension, Cardiogenic shock, Pulmonary fibrosis, Acute respiratory failure, Septic shock, Toxicity to various agents, Red blood cell transfusion, Tricuspid valve incompetence, |
||||
METFORMIN HYDROCHLORIDE, METFORMIN, METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, METFORMIN HYDROCHLORIDE TABLET, METFORMIN HYDROCHLORIDE TABLETS, METHOTREXATE, METHOTREXATE SODIUM, INFLIXIMAB, |
||||
| 893 | 25024099 |
US |
2 | |
Therapy interrupted, |
||||
ISOTRETINOIN, |
||||
| 894 | 25024288 |
39 | 1 | |
Vomiting, Nausea, Therapy interrupted, |
||||
TIRZEPATIDE, SEMAGLUTIDE, |
||||
| 895 | 25024377 |
US |
65 | 2 |
Cervical vertebral fracture, Fall, Off label use, Therapy interrupted, |
||||
ROMOSOZUMAB-AQQG, ROMOSOZUMAB-AQQG, |
||||
| 896 | 25024762 |
US |
44 | 2 |
Device difficult to use, Drug dose omission by device, Device use error, Injection site indentation, Therapy interrupted, |
||||
ERENUMAB-AOOE, ERENUMAB-AOOE, |
||||
| 897 | 25024798 |
US |
49 | 1 |
Psoriatic arthropathy, Therapy interrupted, Insurance issue, Product use in unapproved indication, |
||||
BRODALUMAB, BRODALUMAB, |
||||
| 898 | 25024995 |
US |
50 | 2 |
Device difficult to use, Drug dose omission by device, Therapy interrupted, Product communication issue, |
||||
ETANERCEPT, |
||||
| 899 | 25025356 |
US |
65 | 2 |
Therapy interrupted, |
||||
PANITUMUMAB, PANITUMUMAB, |
||||
| 900 | 25025382 |
EU |
10 | 1 |
Immunosuppression, Sepsis, Gastrointestinal disorder, Biopsy kidney, Photophobia, Aphthous ulcer, Nasopharyngitis, Infection, Headache, Therapy interrupted, |
||||
PREDNISOLONE ACETATE, SOMATROPIN, SOMATROPIN, SOMATROPIN, SIROLIMUS, CYCLOSPORINE, AMLODIPINE, VALSARTAN, SODIUM BICARBONATE, SODIUM BICARBONATE INJECTION,, MAGNESIUM, ERGOCALCIFEROL, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28